Barclays on U.S. IT Hardware: See Potential EPS Upside at DELL and TECD
DELL Hot Sheet
Rating Summary:9 Buy, 14 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Barclays on U.S. IT Hardware: See Potential EPS Upside at DELL and TECD
Analyst, Ben A. Reitzes, said, "...we have raised EPS estimates and price targets for Dell (Nasdaq: DELL) and Tech Data (Nasdaq: TECD). For Dell, the changes are based on share gains vs. HP (NYSE: HPQ) and upside from a 14-week January quarter, as well as some additional sustainability of margins. For Tech Data, we believe the company can benefit near-term from higher margins and solid execution..."
Barclays maintains an 'Equalweight' on Dell, but raises PT from $16 to $19 and raises FY12 from $2.12 to $2.16 and FY13 from $1.80 to $2.05.
Barclays maintains an 'Equalweight' on Tech Data, but raises PT from $48 to $54 and raises FY12 EPS estimate from $4.84 to $5.01 and FY13 from $5.25 to $5.56.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Ben A. Reitzes, said, "...we have raised EPS estimates and price targets for Dell (Nasdaq: DELL) and Tech Data (Nasdaq: TECD). For Dell, the changes are based on share gains vs. HP (NYSE: HPQ) and upside from a 14-week January quarter, as well as some additional sustainability of margins. For Tech Data, we believe the company can benefit near-term from higher margins and solid execution..."
Barclays maintains an 'Equalweight' on Dell, but raises PT from $16 to $19 and raises FY12 from $2.12 to $2.16 and FY13 from $1.80 to $2.05.
Barclays maintains an 'Equalweight' on Tech Data, but raises PT from $48 to $54 and raises FY12 EPS estimate from $4.84 to $5.01 and FY13 from $5.25 to $5.56.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
